Cardiometabolic Effects of Gender-Affirming Hormone Therapy in Transgender Youth
Transgender youth on gender-affirming hormone therapy have differences in their percent fat and lean mass compared with cisgender youth.
Dyslipidemia
DYSLIPIDEMIA
Featured Article
Latest News
Migraine Headache and Risk for Cardiovascular and Cerebrovascular Events
Migraine headache is associated with increased risk for cardiovascular disease and cerebrovascular events, including ischemic stroke.
Impact of BMI on the Outcomes of Intensive LDL-C Lowering Therapy
Patients receiving intensive low-density lipoprotein-cholesterol-lowering therapy may have better clinical outcomes when their body mass index is normal vs high.
Predictors of Cardiovascular Disease in Dysbetalipoproteinemia
Hypertension, smoking, and the levels of triglycerides were found to be independently associated with the risk for cardiovascular disease in patients with dysbetalipoproteinemia.
Impact of Hypertriglyceridemia on Lipoprotein Function in Familial Combined Hyperlipidemia
Patients with familial combined hyperlipidemia may have more severe pro-atherogenic changes in the presence vs absence of hypertriglyceridemia.
Age-Related Differences in Plasma Cholestanol, Lathosterol Found in Pilot Study
There may be age-related differences in the plasma levels of cholestanol and lathosterol as well as in their respective ratios to cholesterol levels.
Is Bariatric Surgery Still Effective on Dyslipidemia 5 Years Later?
The aims of the study were to discover efficacy of bariatric surgery for remission of diseases related to obesity, estimate metabolic changes over 5 years, and compare the outcomes of restrictive and gastric bypass surgeries.
Trial Evaluating Epanova for MACE Risk Reduction Discontinued
AstraZeneca is discontinuing a phase 3 trial evaluating Epanova in patients with mixed dyslipidemia who are at high risk of CVD.
Updated Public Policy Recommendations for Familial Hypercholesterolemia
The adoption of a set of 9 updated public policy recommendations to reduce the clinical and public health burden associated with familial hypercholesterolemia, individual countries can curb atherosclerotic cardiovascular disease in people who carry a gene that predisposes to the disease.
Lipoprotein(a) Reduction With Alirocumab Found to Lower Cardiovascular Risk After ACS
The lowering of lipoprotein(a) with alirocumab was found to independently contribute to the reduction in major adverse cardiovascular events in patients with recent acute coronary syndrome.
Lower Target for LDL-C Levels Reduces Risk for Cardiovascular Events After Stroke
High-intensity statin treatment after ischemic stroke or transient ischemic attack is associated with a reduced risk for subsequent cardiovascular events.
Want to read more?
Please login or register first to view this content.
Next post in Dyslipidemia
